Mikkael A Sekeres

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia
    Hyo Sook Han
    Division of Hematology and Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Leuk Lymphoma 48:1561-8. 2007
  2. ncbi request reprint The challenge of acute myeloid leukemia in older patients
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:24-30. 2002
  3. ncbi request reprint Older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Curr Oncol Rep 4:403-9. 2002
  4. pmc Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
    David P Steensma
    Adult Leukemia Program, Dana Farber Cancer Institute, Boston, MA, USA
    BMC Cancer 16:652. 2016
  5. doi request reprint Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes
    David P Steensma
    Division of Hematological Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 120:1670-6. 2014
  6. ncbi request reprint Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
    Jennifer K Long
    Department of Pharmacy, Clinical Microbiology Section, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mayo Clin Proc 80:1215-6. 2005
  7. ncbi request reprint Non-transplant therapy for older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Natl Compr Canc Netw 4:51-6. 2006
  8. ncbi request reprint Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
    Mikkael A Sekeres
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 103:4036-42. 2004
  9. ncbi request reprint Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 110:1752-9. 2007
  10. ncbi request reprint Thalidomide use and digital gangrene
    Tyler Y Kang
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    J Clin Oncol 24:5328. 2006

Collaborators

Detail Information

Publications12

  1. ncbi request reprint White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia
    Hyo Sook Han
    Division of Hematology and Oncology, Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
    Leuk Lymphoma 48:1561-8. 2007
    ..12 x 10(9)/l HR 1.5, 95%CI 0.96 - 2.37, p = 0.08), as predictors of worse outcomes. Time to WBC nadir predicts survival. The absolute WBC nadir value follows a J-curve, with lower value indicating a worse outcome...
  2. ncbi request reprint The challenge of acute myeloid leukemia in older patients
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Oncol 14:24-30. 2002
    ..Future directions include therapies targeted at immunomodulation, at angiogenesis, and in particular against intracellular signals that promote proliferation at the expense of differentiation...
  3. ncbi request reprint Older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Curr Oncol Rep 4:403-9. 2002
    ..Herein we characterize the intrinsic biologic features of AML as it occurs in the older population, review currently available therapeutic approaches, and discuss therapeutic strategies in development...
  4. pmc Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
    David P Steensma
    Adult Leukemia Program, Dana Farber Cancer Institute, Boston, MA, USA
    BMC Cancer 16:652. 2016
    ....
  5. doi request reprint Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes
    David P Steensma
    Division of Hematological Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 120:1670-6. 2014
    ..Previous studies have suggested that many patients with myelodysplastic syndromes (MDS) have an incomplete understanding of their disease, which may influence adherence to prescribed regimens and outcomes...
  6. ncbi request reprint Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
    Jennifer K Long
    Department of Pharmacy, Clinical Microbiology Section, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mayo Clin Proc 80:1215-6. 2005
    ..No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives...
  7. ncbi request reprint Non-transplant therapy for older adults with acute myeloid leukemia
    Mikkael A Sekeres
    Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Natl Compr Canc Netw 4:51-6. 2006
    ..Clinical trials should be considered at every stage of treatment in this group of patients...
  8. ncbi request reprint Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia
    Mikkael A Sekeres
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Blood 103:4036-42. 2004
    ..African Americans and whites with AML differ with respect to important prognostic factors. African American men have worse CR rates and overall survival than whites and African American women, and should be considered a poor-risk group...
  9. ncbi request reprint Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
    Rachid Baz
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 110:1752-9. 2007
    ..Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization time...
  10. ncbi request reprint Thalidomide use and digital gangrene
    Tyler Y Kang
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    J Clin Oncol 24:5328. 2006
  11. ncbi request reprint Impact of socioeconomic status and distance from treatment center on survival in patients receiving remission induction therapy for newly diagnosed acute myeloid leukemia
    Cristina P Rodriguez
    Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USA
    Leuk Res 32:413-20. 2008
    ..While socioeconomic status (SES) and the distance patients travel to a treatment center (DTC) impact survival of certain solid tumors, little is known of their influence in acute myeloid leukemia (AML)...
  12. ncbi request reprint New data with arsenic trioxide in leukemias and myelodysplastic syndromes
    Mikkael A Sekeres
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Lymphoma Myeloma 8:S7-S12. 2007
    ....